VALVE DISEASE: Anticoagulation in valvar heart disease: new aspects and management during non-cardiac surgery
Open Access
- 1 November 2000
- Vol. 84 (5) , 567-572
- https://doi.org/10.1136/heart.84.5.567
Abstract
He indications for oral anticoagulant treatment have been extended over the last 10 years. The detection of new congenital thrombophilic risk factors, the stud- ies on non-valvar atrial fibrillation, and the increase in valvar heart surgery have all led to a rise in the number of patients being treated. In 1997, 64 000 valve operations were performed across Europe; in two thirds of these operations mechanical prostheses were used, subsequently requiring lifelong oral anticoagulant treat- ment. w1Keywords
This publication has 14 references indexed in Scilit:
- Low Molecular Weight Heparin After Mechanical Heart Valve ReplacementCirculation, 2000
- Perioperative bleeding and thromboembolic risk during non-cardiac surgery in patients with mechanical prosthetic heart valves: an institutional review.1999
- Correction of Excessive Anticoagulation with Low-Dose Oral Vitamin K_1Annals of Internal Medicine, 1997
- AREVA: Multicenter Randomized Comparison of Low-Dose Versus Standard-Dose Anticoagulation in Patients With Mechanical Prosthetic Heart ValvesCirculation, 1996
- Guidelines for prevention of thromboembolic events in valvular heart diseaseEuropean Heart Journal, 1995
- Temporary Discontinuation of Warfarin Therapy: Changes in the International Normalized RatioAnnals of Internal Medicine, 1995
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)The Lancet, 1994
- Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.Circulation, 1994
- A Comparison of Aspirin with Placebo in Patients Treated with Warfarin after Heart-Valve ReplacementNew England Journal of Medicine, 1993
- Effective reversal of warfarin-induced excessive anticoagulation with low dose vitamin K1.1992